Table 1 Patients’ baseline clinical characteristics
From: Does mRNA SARS-CoV-2 vaccine influence patients' performance during IVF-ET cycle?
| Â | Female | Male |
|---|---|---|
Number of patients | 36 | 36 |
Mean interval between OPU cycles / Sperm test (months) | 5.2 ± 6.1 | 4.2 ± 4.9 |
(Range) | (1–24) | (0–23) |
Mean interval between Second Vaccination to OPU cycle / Sperm test (days) | 32.6 ± 17.5 | 33.3 ± 14.9 |
(Range) | (7–85) | (7–85) |
Age, years (mean ± SD) | 37.3 ± 4.6 | 40.1 ± 4.8 |
Gravida (mean ± SD) | 2 ± 1.5 | --- |
Para (mean ± SD) | 0.9 ± 0.9 | --- |
Smoking (%) | 3/36 (8.3) | --- |
BMI, Kg/m2 (mean ± SD) | 26.3 ± 5.4 | --- |
Mean basal FSH IU/L (mean ± SD) | 8.2 ± 3.8 | --- |
Mean basal LH IU/L (mean ± SD) | 5.1 ± 2.5 | --- |
Type of infertility | Â | Â |
Male (%) | 6/36 (16.7) | |
Tubal (%) | 1/36 (2.8) | |
Endometriosis (%) | 4/36 (11.1) | |
Unexplained infertility (%) | 4/36(11.1) | |
Ovulatory disorder (%) | 1/36 (2.8) | |
Uterine factor (%) | 1/36 (2.8) | |
Others (%) | 26/36 (72.2) | |